Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Zelira Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$8.00 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
11.35 million
Earnings per share
-3.236
Dividend per share
N/A
Year To Date Return
-21.67%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Zelira Therapeutics Ltd (ASX: ZLD)
Latest News
⏸️ Investing
These 3 ASX shares just raced to 52-week highs: Can they keep going?
⏸️ Investing
Here's why these 4 ASX shares have surged higher today
⏸️ Investing
Why the Zelda Therapeutics Ltd share price has surged higher today
⏸️ Investing
My Top 5 Investing Predictions for the Rest of 2017
⏸️ Investing
Here's why these 4 ASX shares have surged higher today
⏸️ Investing
These 3 ASX shares just hit all-time highs: Can they go higher?
⏸️ Investing
Why these 4 ASX shares have SMASHED the market today
⏸️ Investing
Here's why these 6 explosive ASX shares have smashed the market in March
⏸️ Investing
Why these 4 ASX shares have started the week with a BANG
⏸️ Investing
Why these 4 ASX shares have soared today
⏸️ Investing
Zelda Therapeutics Ltd's share price rockets: Is the pot stock a buy?
⏸️ Investing
Why the marijuana sector is at risk of becoming a joke
ZLD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Zelira Therapeutics Ltd
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
ZLD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 26 Apr 2024 | $0.71 | $-0.01 | -1.41% | 269 | $0.70 | $0.71 | $0.70 |
| 24 Apr 2024 | $0.71 | $0.01 | 1.43% | 1,279 | $0.71 | $0.72 | $0.71 |
| 23 Apr 2024 | $0.70 | $0.01 | 1.45% | 174 | $0.70 | $0.70 | $0.70 |
| 22 Apr 2024 | $0.69 | $-0.02 | -2.82% | 490 | $0.71 | $0.71 | $0.69 |
| 19 Apr 2024 | $0.71 | $-0.01 | -1.39% | 3,894 | $0.72 | $0.72 | $0.71 |
| 18 Apr 2024 | $0.72 | $0.01 | 1.41% | 6,518 | $0.72 | $0.72 | $0.71 |
| 17 Apr 2024 | $0.71 | $-0.01 | -1.39% | 7,495 | $0.72 | $0.72 | $0.71 |
| 16 Apr 2024 | $0.72 | $0.01 | 1.41% | 515 | $0.73 | $0.73 | $0.72 |
| 15 Apr 2024 | $0.71 | $0.02 | 2.90% | 3,516 | $0.69 | $0.75 | $0.69 |
| 12 Apr 2024 | $0.69 | $0.00 | 0.00% | 1,386 | $0.69 | $0.72 | $0.69 |
| 11 Apr 2024 | $0.69 | $-0.01 | -1.43% | 1,968 | $0.70 | $0.71 | $0.69 |
| 10 Apr 2024 | $0.70 | $0.00 | 0.00% | 1,942 | $0.69 | $0.70 | $0.69 |
| 09 Apr 2024 | $0.70 | $0.01 | 1.44% | 3,220 | $0.70 | $0.70 | $0.70 |
| 08 Apr 2024 | $0.70 | $-0.01 | -1.43% | 957 | $0.69 | $0.70 | $0.69 |
| 05 Apr 2024 | $0.70 | $0.00 | 0.00% | 2,359 | $0.70 | $0.70 | $0.70 |
| 04 Apr 2024 | $0.70 | $0.00 | 0.00% | 635 | $0.70 | $0.70 | $0.70 |
| 03 Apr 2024 | $0.70 | $0.01 | 1.46% | 7,408 | $0.69 | $0.70 | $0.69 |
| 02 Apr 2024 | $0.69 | $-0.01 | -1.43% | 3,796 | $0.70 | $0.70 | $0.68 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 24 Nov 2023 | Timothy (Tim) Slate | Issued | 100,000 | $47,335 |
Director remuneration.
|
| 24 Nov 2023 | Oludare Odumosu | Issued | 200,000 | $94,669 |
Director remuneration. As per announcement on 24-11-2023
|
| 24 Nov 2023 | Osagie Imasogie | Issued | 150,000 | $71,002 |
Director remuneration.
|
| 24 Nov 2023 | Greg Blake | Issued | 175,000 | $82,836 |
Director remuneration.
|
| 24 Nov 2023 | Donna O'Donnell | Issued | 145,000 | $91,430 |
Director remuneration.
|
| 11 Sep 2023 | Greg Blake | Expiry | 114,290 | $113,147 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Timothy (Tim) Ryan Slate | Company SecretaryNon-Executive Director | Dec 2016 |
Mr Slate provides accounting and secretarial advice to private and public companies. Mr Slate has over 15 years of experience in chartered accounting.
|
| Dr Oludare Odumosu | Managing Director | Dec 2019 |
Dr Odumosu has over 10 years in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a combination of experiences from several academic, public health and life science organizations.
|
| Mr Osagie Imasogie | Non-Executive ChairmanNon-Executive Director | Dec 2019 |
Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President.
|
| Mr Greg Blake | Executive Director | Feb 2023 |
Mr Blake has led the strategic development and commercialization of several products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a foundation of knowledge across marketing and the entire commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch pathway and commercialization planning for both domestic and international markets.
|
| Dr Donna Gentile O'Donnell | Non-Executive Director | Jun 2023 |
Dr O'Donnell served as Special Assistant to the President, Dr. Stephen K Klasko, and is Senior Vice President for Innovation Partnerships and Programs at Thomas Jefferson University. Donna has led a diverse career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organizations, universities, and life science companies, including Cephalon Pharmaceuticals. She was previously the managing director of the Eastern Technology Council for nine years.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Malik Majeed | 1,134,644 | 10.00% |
| Quincy Street Capital Llc | 456,622 | 4.02% |
| Sharri J Rochlin <Rochlin Family Resource A/C> | 393,168 | 3.46% |
| Osagie Imasogie | 393,168 | 3.47% |
| Mr Zoltan Kerekes | 393,168 | 3.46% |
| Sunset Capital Management Pty Ltd <Sunset Superfund A/C> | 383,725 | 3.38% |
| Ms Lisa Gray | 381,988 | 3.37% |
| Mera I Llc\C | 332,479 | 2.93% |
| Mr Torsten M Geers <The Torsten M Geers Living A/C> | 307,454 | 2.71% |
| Mr Steve Shapiro | 302,571 | 2.67% |
| Mara Gordon | 252,242 | 2.22% |
| Ubs Nominees Pty Ltd | 160,689 | 1.42% |
| Mr Saul Shorr and Mrs Margaret Shorr | 151,285 | 1.33% |
| Dr Chanda Latrice Macias | 146,479 | 1.29% |
| Mera Ii Llc\C | 133,372 | 1.18% |
| Citicorp Nominees Pty Limited | 132,506 | 1.17% |
| Oludare Odumosu | 131,766 | 1.16% |
| Muller Ct Pty Ltd <Muller Super Fund A/C> | 118,107 | 1.04% |
| Mr Daniel Hexter and Mrs Shannon Hexter | 103,389 | 0.91% |
| Geers Egag Llc | 85,715 | 0.76% |
